Amgen lines up new AI biotech partner in PostEra to develop small molecule medicines
Amgen is enlisting AI startup PostEra for a drug discovery deal for five small molecule programs, PostEra announced Thursday morning.
Few details about the collaboration were made available. PostEra CEO Aaron Morris declined to comment on the deal value in an interview with Endpoints News. However, he described it as the “most meaningful partnership we’ve done to date,” and added that it brings the total deal value PostEra has closed to over $1 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.